Certain identified information has been excluded from this exhibit because such information both (i) is not material and (ii) would likely cause competitive harm if publicly disclosed. Excluded information is indicated with brackets and asterisks.Confidential Letter Agreement • May 4th, 2022 • REGENXBIO Inc. • Biological products, (no disgnostic substances) • Pennsylvania
The purpose of this letter agreement (the “2022 Letter Agreement”) is to amend aspects of the Parties’ relationship and also to memorialize the terms of a confidential settlement of potential claims between The Trustees of the University of Pennsylvania (“Penn”) and REGENXBIO Inc. (“REGENXBIO”), effective as of March 21, 2022 (the “Effective Date”). Penn and REGENXBIO each may be referred to herein as a “Party,” and collectively as the “Parties.” This letter also serves to release GSK from certain claims by REGENXBIO that REGENXBIO had, has, or may have under various agreements listed below.
PROMETHEUM, INC. NEW YORK, NEW YORK 10005Confidential Letter Agreement • May 11th, 2018 • Prometheum, Inc. • Security & commodity brokers, dealers, exchanges & services
This Confidential Letter Agreement shall memorialize our understanding regarding your relationship with Prometheum, Inc. (the “Company”).
